How to choose a healthcare AI implementation partner: 8 questions to ask before you sign

Introduction

Most healthcare AI failures are partner failures, not technology failures. Over 80% of AI projects fail to reach production, and healthcare compounds every general implementation risk with regulatory exposure, clinical safety obligations, and integration environments that no off-the-shelf solution was designed for.

Today, most healthcare organisations evaluate AI vendor selection healthcare using procurement frameworks designed for software purchases: comparing feature lists, requesting demos, checking compliance certificates. The problem is that healthcare agentic AI deployment is not a software purchase. It is a continuous operational system embedded in clinical and administrative workflows, one that must integrate with fragmented data environments, operate under HIPAA, and remain observable and maintainable long after the vendor has rolled off.

“Companies should treat AI vendor selection as a strategic partnership and not a technology purchase.”

Simone Colgan Dunlap, attorney at Quarles & Brady. Clinical Leader, December 2025

The eight questions below are structured to surface what a sales process will not show you. Ask them in the first meeting. The answers will tell you more than any demo.

Question 1: How many AI systems have you deployed in production in healthcare, not pilots?

The jump from prototype to production is where most projects fail. Gartner data shows only 48% of AI projects reach production, with an average of eight months between prototype and go-live. In healthcare, the gap widens further because of integration complexity, compliance requirements, and clinical change management.

Current approach: Today, healthcare procurement teams review vendor case studies and reference client lists without distinguishing between pilots and deployed systems. Vendors rarely volunteer the distinction. A system that ran for six weeks in a controlled trial and a system processing live claims for 100,000 members are presented identically.

What a strong answer looks like: Named production systems, specific operational outcome metrics, and client references who can describe the system in live operation today.

Red flag: “We have worked with 50 healthcare organisations” without specifying how many are in active production use.

At Vstorm, our 30+ agentic implementations include production-grade systems running in US healthcare settings: a multi-channel pre-appointment AI agent deployed for a Medicare Advantage provider serving over 100,000 members, and claim-processing automation for a leading US healthcare insurer. These are not pilots; they are operational systems with measurable outcomes. Read the case studies at vstorm.co.

Question 2: How will your system integrate with our EHR and existing clinical infrastructure?

Healthcare data does not live in one place. Electronic health records, lab systems, billing platforms, imaging archives, and scheduling tools all operate on different standards and update cycles. Guidehouse (December 2025) found that over 40% of healthcare leaders cite data quality, standardisation, and governance as the primary barrier to AI deployment. A Springer Nature study published in January 2026 confirmed that limited interoperability remains one of the top structural failure points for agentic AI in clinical settings.

Current approach: Integration planning is typically deferred to a technical kickoff meeting after contracts are signed, by which point the vendor’s architecture is already fixed. The client then absorbs the integration cost.

What a strong answer looks like: Named EHR platforms the partner has integrated with (Epic, Cerner, Meditech, Athena), a clear approach to HL7/FHIR compatibility, and examples of handling data from multiple source systems simultaneously.

Red flag: “Our system is EHR-agnostic” with no specifics on integration patterns or past integration projects. Agnosticism is not the same as capability.

When we deployed the pre-appointment AI agent for a US Medicare Advantage provider, seamless integration with the client’s clinic management and physician management platforms was a design constraint from day one, not an afterthought. The system required no manual data re-entry and updated patient records automatically after each interaction. Full case study: vstorm.co/case-study/multi-channel-ai-agent-in-healthcare

Question 3: How do you handle HIPAA compliance, data governance, and PHI?

Any vendor processing protected health information must sign a Business Associate Agreement. However, a signed BAA is a legal floor, not a compliance guarantee. Foley & Lardner (May 2025) notes that AI systems introduce specific risks that standard security reviews do not cover: model training on PHI, inference-level logging gaps, and prompt injection vulnerabilities. In January 2025, HHS published a Notice of Proposed Rulemaking for the first major HIPAA Security Rule update in 20 years, removing the distinction between required and addressable safeguards and introducing mandatory requirements for encryption, multi-factor authentication, and breach response. OCR has kept finalization on its official regulatory agenda for May 2026, with a 240-day compliance window once the final rule is published. (Alston & Bird, November 2025)

Current approach: Healthcare procurement teams request BAA documentation and check for SOC 2 certification. Most stop there, without asking whether the vendor’s model was trained on patient data, whether PHI stays in a dedicated instance, or what happens to data when the contract ends.

Minimum certifications to ask for: SOC 2 Type II, HITRUST CSF (r2 preferred), ISO 27001.

Specific questions to ask within this conversation:

• Does my PHI stay in a dedicated instance?
• Is my data used to fine-tune your base model?
• What is your breach notification SLA?

Red flag: Self-attestation only, vague “HIPAA-ready” language, no third-party audit report available on request.

Question 4: When did clinicians first provide input on this solution?

Sully.ai’s 2025 Implementation Guide found that 82% of clinical AI development efforts consult clinicians only at later stages, after core algorithms and interfaces are already built. Half gather user feedback only after development is complete, when addressing workflow misalignment requires costly rebuilding.

Systems built without clinical design partnership consistently miss how care delivery actually works. They generate alert fatigue, create manual workarounds, and add to administrative burden rather than reducing it.

Current approach: Vendors reference clinical advisors or advisory boards in sales materials. The question is not whether clinicians were involved, but at what stage and in what capacity.

What a strong answer looks like: Clinicians were design partners from the outset, shaping the problem definition, the interaction model, and the integration logic. Their input changed what was built, not just how it was presented.

Red flag: “We validated with clinicians” with no answer to when, how, or what changed as a result. Validation after completion is not design partnership.

When we built the triage chatbot for Schmitt-Thompson Clinical Content (STCC), whose nurse triage guidelines serve 95% of medical call centres in North America, clinical workflow requirements shaped every architectural decision from the first sprint. vstorm.co

Question 5: How will we define and measure success after go-live?

McKinsey’s Q4 2024 survey of 150 US healthcare leaders found that 64% of organisations that had implemented gen AI use cases reported positive or anticipated positive ROI. Yet the same survey found that the majority of respondents had not yet calculated returns, and 15% had not started proof-of-concept work at all. The organisations most likely to realise ROI are those that define what success looks like operationally before deployment begins. Gartner found that only 48% of AI projects reach production and that the average prototype-to-production timeline is eight months: organisations without pre-defined success criteria have no reliable way to determine whether that investment was justified.

Current approach: Success criteria are set during procurement in technical terms: accuracy scores, latency benchmarks, uptime guarantees. Operational measures such as time saved per clinician, claim denial rates, and patient engagement rates are rarely captured at baseline before deployment, making post-launch evaluation impossible.

What a strong answer looks like: A partner who proposes specific, measurable operational outcomes in the scoping phase, captures a baseline before go-live, and ties delivery milestones to those outcomes.

Red flag: “Success looks like what you need it to look like.” Outcome-agnostic language transfers all measurement risk to the client.

When we deployed the pre-appointment agent for the US Medicare Advantage provider, outcomes were defined before engineering began: each doctor saving more than five hours per week, patient engagement increasing by over 20%. Both were achieved. vstorm.co/case-study/multi-channel-ai-agent-in-healthcare

Question 6: What does your discovery process look like before engineering begins?

Orion Health (January 2026) identifies poor problem definition as one of the top causes of healthcare AI failure. Organisations build solutions for problems they have not fully understood, because the partner did not invest sufficient time in understanding current-state workflows before proposing an architecture.

Current approach: Healthcare AI projects frequently begin with a requirements document written by an internal team and passed to an engineering partner. This produces systems that technically meet the specification but fail operationally, because the specification did not capture how the process actually runs, where it breaks, or what constraints govern it.

What a strong answer looks like: A defined discovery phase that maps current-state workflows, identifies integration constraints, surfaces data quality issues, and produces a feasibility-grounded project brief before any code is written. The discovery output should include a clear view of which use cases are viable for agentic AI and which are not.

Red flag: “We can start building in week two.” Rapid starts signal a partner optimised for demonstrating momentum, not for delivering production systems. In healthcare specifically, the processes that most need automation are also the most operationally complex.

Vstorm’s TriStorm methodology structures discovery before any agentic engineering begins, treating process mapping and feasibility assessment as a delivery phase in their own right. vstorm.co/tristorm

Question 7: Who will own and maintain the system after you roll off, and what is your knowledge transfer plan?

System ownership after delivery is one of the clearest differentiators between a partner and a vendor. Architectures built on proprietary platforms leave healthcare organisations unable to modify, audit, or maintain their own AI systems. The EU AI Act provisions for high-risk systems take effect in August 2026 and will require organisations to demonstrate governance and oversight of deployed AI (Censinet, February 2026): that requires genuine system ownership, not licence access.

Current approach: Healthcare organisations sign implementation contracts and receive a deployed system with minimal documentation. System changes require re-engagement with the original vendor at additional cost. Internal teams have no visibility into model behaviour or integration logic.

What a strong answer looks like: Open-source architecture with full code ownership transferred to the client, structured knowledge transfer throughout the build (not as a final handover session), and documentation sufficient for internal teams to maintain and extend the system independently.

Red flag: Proprietary platform with restricted API access. Knowledge transfer described as a training session at project close. Any framing that positions continued vendor engagement as the only path to system changes.

Question 8: How do you monitor the system in production, and how do you handle regulatory changes?

Agentic AI systems degrade over time when clinical workflows, data distributions, or regulatory requirements change. Censinet (February 2026) identifies inference-level logging, drift detection, and retraining protocols as minimum requirements for safe production deployment in healthcare. The regulatory landscape is also shifting actively: the HIPAA Security Rule update, with finalization expected in May 2026 and a 240-day compliance window thereafter (Alston & Bird); EU AI Act high-risk AI provisions taking effect 2 August 2026 (European Commission); and evolving FDA guidance on AI-enabled medical devices: all create ongoing compliance obligations that extend well beyond the go-live date.

Current approach: Most healthcare AI deployments ship with application-level monitoring but no AI-specific observability: no tracing of agent decisions, no output drift detection, no automated performance degradation alerts. Compliance obligations post-deployment are typically addressed only when an audit or incident surfaces a gap.

What a strong answer looks like: An observability framework built into the system from day one, not added later. Clear protocols for retraining, model updates, and regulatory change response. A named process for informing clients of changes that affect their compliance posture.

Red flag: “We will handle any issues as they arise.” Reactive maintenance of a clinical AI system is a patient safety and compliance risk. In healthcare, observability is not optional.

Summary: what you are testing with each question

What these questions look like in practice

When a US Medicare Advantage provider serving over 100,000 members approached Vstorm, the engagement began with structured discovery: mapping the pre-appointment workflow across multiple clinics, identifying data sources, surfacing integration constraints, and defining measurable outcomes before any engineering began. The system was built on open-source architecture, integrated with the client’s existing platforms, and designed with clinicians as active design participants throughout. Each doctor now saves more than five hours per week. Patient engagement has increased by over 20%.

The same approach applies across Vstorm’s healthcare engagements: claim processing automation for a US healthcare insurer and clinical triage tooling for STCC. These are not checklists for qualification. They are the questions a serious partner asks itself before proposing anything.

Explore Vstorm’s healthcare implementations

Conclusion

Choosing a healthcare AI implementation partner is not a procurement decision. It is an operational one. The eight questions above will not appear in a vendor’s demo script, which is precisely why they are worth asking. A partner with production-grade experience in healthcare will answer each question specifically, with named systems, named certifications, named outcomes, and a named plan for what happens after deployment. One who cannot is not ready to operate inside a clinical environment.

Frequently asked questions

What certifications should a healthcare AI implementation partner hold?

At minimum: SOC 2 Type II, HITRUST CSF (r2 certification is the current gold standard), and ISO 27001. If the system qualifies as a medical device or clinical decision support tool, ask about FDA clearance status. Certifications confirm the security posture at a point in time; they do not replace ongoing auditing and monitoring.

What is a Business Associate Agreement and why does it matter for AI vendors?

A Business Associate Agreement (BAA) is the legal contract required under HIPAA whenever a third-party vendor processes, transmits, or stores protected health information on behalf of a covered entity. For AI systems, a BAA must address not just data storage but also inference-level logging, model training on PHI, and breach notification timelines. A signed BAA is a legal floor; it does not guarantee that a vendor’s AI system is actually secure or compliant.

What is the difference between a healthcare AI pilot and a production deployment?

A pilot is a time-bounded, often controlled test of a system with a defined group of users and limited operational scope. A production deployment is a live system integrated into real workflows, processing real data, and operating under full compliance obligations. The majority of vendor case studies describe pilots. Ask specifically how many of a vendor’s healthcare engagements are in live production operation today.

How do I evaluate a healthcare AI vendor’s clinical validation claims?

Ask when clinicians first provided input on the solution, what changed as a result of that input, and whether clinicians were design partners throughout the build or reviewers at the end. Ask for external validation studies, not just internal performance reports. The Epic sepsis model, for example, achieved strong internal AUC scores but showed an 88% false positive rate in external validation. Internal benchmarks are not a substitute for real-world performance data.

What does observability mean in the context of healthcare agentic AI?

Observability in agentic AI refers to the ability to trace and audit every agent decision in production: what inputs the agent received, what reasoning it applied, what outputs it produced, and whether those outputs changed over time. In healthcare, this includes inference-level logging of interactions involving PHI, drift detection to identify when model performance degrades, and alerts when outputs fall outside expected parameters. Observability is a patient safety requirement, not just a technical preference.

What healthcare AI regulations should implementation partners comply with in 2025 and 2026?

In the US: HIPAA Privacy Rule and HIPAA Security Rule (major update proposed January 2025; finalization expected by HHS’s own regulatory agenda in May 2026, with a 240-day compliance window once enacted), and FDA guidance for AI-enabled medical devices where applicable. In the EU: the EU AI Act, with high-risk AI system provisions taking effect 2 August 2026, confirmed by the Council of the EU as recently as 7 May 2026. Implementation partners should be able to speak to each of these specifically and demonstrate how their delivery approach addresses compliance obligations across the full deployment lifecycle, not just at go-live.

How does agentic AI differ from traditional healthcare automation tools?

Traditional automation tools in healthcare, including robotic process automation (RPA) and rule-based workflow software, execute fixed, predefined sequences. They do not plan, adapt, or coordinate across systems. Agentic AI systems are goal-directed: they can decompose complex tasks, retrieve information from multiple sources, make context-aware decisions, and take action across integrated platforms. In healthcare, this means an agentic system can manage a multi-step pre-appointment workflow, a claim adjudication sequence, or a triage protocol end-to-end, rather than automating individual steps in isolation.

What is the risk of choosing a healthcare AI partner primarily on price?

Price-first selection consistently correlates with two outcomes: under-scoped discovery (the partner skips the process mapping that determines whether the solution will work in operations) and under-specified ownership terms (the client ends up with a proprietary system they cannot modify, audit, or maintain independently). In healthcare, the downstream cost of a system that fails in production, or that requires continuous vendor involvement to stay operational, typically exceeds the initial cost saving by a significant margin.

Last reviewed: May 2026. Sources last verified: May 2026.